By using monoclonal antibodies against immune checkpoints (ipilimumab against CTLA-4, or nivolumab and pembrolizumab against PD1), cancer immunotherapy effectively releases tumor-induced immune system brakes to restart cancer immune circulation (Tan et al., 2017). Here, CTLA4 is linked to cancer.